抗血小板基因治疗在冠心病治疗中的研究进展
Research Progress of Antiplatelet Gene Therapy in the Treatment of Coronary Heart Disease
DOI: 10.12677/jcpm.2025.44447, PDF,   
作者: 刘 畅：济宁医学院临床医学院，山东 济宁；范康钧, 程前进*：济宁医学院附属医院心脏外科，山东 济宁
关键词: 基因治疗；抗血小板；冠心病；文献综述；Gene Therapy； Antiplatelet； Coronary Heart Disease； Literature Review
摘要: 冠心病(Coronary Heart Disease, CHD)是全球心血管疾病死亡的首要原因，每年的发病率和死亡率也在逐年上升。其病理核心是动脉粥样硬化斑块破裂后血小板活化介导的血栓形成。传统抗血小板药物(如阿司匹林、P2Y12抑制剂)虽能有效降低血栓事件，但存在个体疗效差异、出血风险高和患者依从性差等缺陷。基因治疗通过靶向调控血小板功能相关基因的表达，为实现精准、长效且局部化的抗栓治疗提供了革命性策略。本文系统综述抗血小板基因治疗的关键基因、递送载体、临床前研究进展及转化医学挑战，并结合最新技术趋势展望其未来发展方向。
Abstract: Coronary Heart Disease (CHD) is the leading cause of death from cardiovascular disease worldwide, and the annual morbidity and mortality are also increasing year by year. Its pathological core is platelet activation-mediated thrombosis after atherosclerotic plaque rupture. Traditional antiplatelet drugs (such as aspirin, P2Y12 inhibitors) can effectively reduce thrombotic events, but there are some defects such as individual differences in efficacy, high risk of bleeding and poor patient compliance. Gene therapy provides a revolutionary strategy for achieving accurate, long-term and localized antithrombotic therapy by targeting the expression of platelet function-related genes. This article systematically reviews the key genes, delivery vectors, preclinical research progress and translational medicine challenges of antiplatelet gene therapy, and looks forward to its future development direction in combination with the latest technological trends.
文章引用：刘畅, 范康钧, 程前进. 抗血小板基因治疗在冠心病治疗中的研究进展[J]. 临床个性化医学, 2025, 4(4): 294-302. https://doi.org/10.12677/jcpm.2025.44447

参考文献

[1] Roth, G.A., Mensah, G.A., Johnson, C.O., et al. (2020) Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. Journal of the American College of Cardiology, 76, 2982-3021.
[2] 刘明波, 何新叶, 杨晓红, 等.《中国心血管健康与疾病报告2023》要点解读[J]. 中国心血管杂志, 2024, 29(4): 305-324.
[3] Lee, C.R., Luzum, J.A., Sangkuhl, K., Gammal, R.S., Sabatine, M.S., Stein, C.M., et al. (2022) Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clinical Pharmacology & Therapeutics, 112, 959-967.
[4] Ned, R.M. (2010) Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: Current Evidence and Test Availability. Application: Pharmacogenomics. PLOS Currents, 2, RRN1180. [Google Scholar] [CrossRef] [PubMed]
[5] Rothenbacher, D., Hoffmann, M.M., Breitling, L.P., Rajman, I., Koenig, W. and Brenner, H. (2013) Cytochrome P450 2C19*2 Polymorphism in Patients with Stable Coronary Heart Disease and Risk for Secondary Cardiovascular Disease Events: Results of a Long-Term Follow-Up Study in Routine Clinical Care. BMC Cardiovascular Disorders, 13, Article No. 61. [Google Scholar] [CrossRef] [PubMed]
[6] Xi, Z., Fang, F., Wang, J., AlHelal, J., Zhou, Y. and Liu, W. (2017) CYP2C19 Genotype and Adverse Cardiovascular Outcomes after Stent Implantation in Clopidogrel-Treated Asian Populations: A Systematic Review and Meta-Analysis. Platelets, 30, 229-240. [Google Scholar] [CrossRef] [PubMed]
[7] Palmerini, T., Bruno, A.G., Gilard, M., Morice, M., Valgimigli, M., Montalescot, G., et al. (2019) Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration after Drug-Eluting Stent Implantation in Relation to Clinical Presentation. Circulation: Cardiovascular Interventions, 12, e007541. [Google Scholar] [CrossRef] [PubMed]
[8] Palmerini, T., Bruno, A.G., Redfors, B., Valgimigli, M., Taglieri, N., Feres, F., et al. (2021) Risk-Benefit of 1-Year DAPT after DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. Journal of the American College of Cardiology, 78, 1968-1986. [Google Scholar] [CrossRef] [PubMed]
[9] 中华医学会心血管病学分会动脉粥样硬化与冠心病学组, 中华医学会心血管病学分会介入心脏病学组, 中国医师协会心血管内科医师分会血栓防治专业委员会, 等. 冠心病双联抗血小板治疗中国专家共识[J]. 中华心血管病杂志, 2021, 49(5): 432-454.
[10] LaRosa, A.R., Swabe, G.M. and Magnani, J.W. (2022) Income and Antiplatelet Adherence Following Percutaneous Coronary Intervention. International Journal of Cardiology Cardiovascular Risk and Prevention, 14, Article 200140. [Google Scholar] [CrossRef] [PubMed]
[11] Luu, N.M., Dinh, A.T., Nguyen, T.T.H. and Nguyen, V.H. (2019) Adherence to Antiplatelet Therapy after Coronary Intervention among Patients with Myocardial Infarction Attending Vietnam National Heart Institute. BioMed Research International, 2019, Article ID: 6585040.
[12] Rasko, J.E.J., Samelson-Jones, B.J., George, L.A., Giermasz, A., Ducore, J.M., Teitel, J.M., et al. (2025) Fidanacogene Elaparvovec for Hemophilia B—A Multiyear Follow-Up Study. New England Journal of Medicine, 392, 1508-1517. [Google Scholar] [CrossRef] [PubMed]
[13] Pereira, N.L., Rihal, C., Lennon, R., Marcus, G., Shrivastava, S., Bell, M.R., et al. (2021) Effect of CYP2C19 Genotype on Ischemic Outcomes during Oral P2Y12 Inhibitor Therapy: A Meta-Analysis. JACC: Cardiovascular Interventions, 14, 739-750. [Google Scholar] [CrossRef] [PubMed]
[14] Jiang, Q., Huang, K., Yin, L., Kong, H., Yang, Z. and Hu, S. (2024) Effect of Ticagrelor versus Clopidogrel after Off-Pump Coronary Artery Bypass Grafting on Postoperative Atrial Fibrillation: A Cohort Study. Journal of the American Heart Association, 13, e035424. [Google Scholar] [CrossRef] [PubMed]
[15] 龚磊. CYP2 C19: 氯吡格雷代谢的关键酶? [J]. 心血管病学进展, 2017, 38(2): 222-225.
[16] 张爱玲, 杨莉萍, 胡欣. 亚洲健康人群CYP2C19等位基因发生率的合并分析[J]. 中国循证医学杂志, 2013, 13(12): 1431-1439.
[17] Bhat, K.G., Pillai, R.K.J., Lodhi, H., Guleria, V.S., Abbot, A.K., Gupta, L., et al. (2023) Pharmacogenomic Evaluation of CYP2C19 Alleles Linking Low Clopidogrel Response and the Risk of Acute Coronary Syndrome in Indians. The Journal of Gene Medicine, 26, e3634. [Google Scholar] [CrossRef] [PubMed]
[18] 曹银银, 潘其扬, 李健, 等. 川崎病合并冠状动脉病变患儿氯吡格雷抵抗与基因变异性的关系[J]. 中华儿科杂志, 2024, 62(10): 981-988.
[19] Bhattacharyya, T. Nicholls, S.J., Topol, E.J., et al. (2008) Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity with Systemic Oxidative Stress and Cardiovascular Risk. JAMA, 299, 1265-1276. [Google Scholar] [CrossRef] [PubMed]
[20] Pan, Y., Chen, W., Wang, Y., Li, H., Johnston, S.C., Simon, T., et al. (2019) Association between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients with Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. JAMA Neurology, 76, 552-560. [Google Scholar] [CrossRef] [PubMed]
[21] Asmamaw Mengstie, M., Teshome Azezew, M., Asmamaw Dejenie, T., Teshome, A.A., Tadele Admasu, F., Behaile Teklemariam, A., et al. (2024) Recent Advancements in Reducing the Off-Target Effect of CRISPR-Cas9 Genome Editing. Biologics: Targets and Therapy, 18, 21-28. [Google Scholar] [CrossRef] [PubMed]
[22] Kato-Inui, T., Takahashi, G., Hsu, S. and Miyaoka, Y. (2018) Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-Associated Protein 9 with Improved Proof-Reading Enhances Homology-Directed Repair. Nucleic Acids Research, 46, 4677-4688. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, L., Che, C., Du, Y., Han, L., Wang, J., Zhang, C., et al. (2025) N-Homocysteinylation of β-Arrestins Biases GPCR Signaling and Promotes Platelet Activation. Blood, 145, 2374-2389. [Google Scholar] [CrossRef] [PubMed]
[24] Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. and Gregory, P.D. (2010) Genome Editing with Engineered Zinc Finger Nucleases. Nature Reviews Genetics, 11, 636-646. [Google Scholar] [CrossRef] [PubMed]
[25] Christian, M., Cermak, T., Doyle, E.L., et al. (2010) Targeting DNA Double-Strand Breaks with TAL Effector Nucleases. Genetics, 186, 757-761. [Google Scholar] [CrossRef] [PubMed]
[26] Gupta, R.M. and Musunuru, K. (2014) Expanding the Genetic Editing Tool Kit: ZFNs, TALENs, and CRISPR-Cas9. Journal of Clinical Investigation, 124, 4154-4161. [Google Scholar] [CrossRef] [PubMed]
[27] 徐学武, 俞卫锋. 第三代腺病毒载体的研究进展[J]. 生物技术, 2005, 15(3): 79-82.
[28] Goepfert, C., Imai, M., Brouard, S., Csizmadia, E., Kaczmarek, E. and Robson, S.C. (2000) CD39 Modulates Endothelial Cell Activation and Apoptosis. Molecular Medicine, 6, 591-603. [Google Scholar] [CrossRef] [PubMed]
[29] Muruve, D.A. (2004) The Innate Immune Response to Adenovirus Vectors. Human Gene Therapy, 15, 1157-1166. [Google Scholar] [CrossRef] [PubMed]
[30] Naso, M.F., Tomkowicz, B., Perry, W.L. and Strohl, W.R. (2017) Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs, 31, 317-334. [Google Scholar] [CrossRef] [PubMed]
[31] Li, F., Yang, X., Liu, J., Shu, K., Shen, C., Chen, T., et al. (2019) Antithrombotic Effect of ShRNA Target F12 Mediated by Adeno-Associated Virus. Molecular Therapy-Nucleic Acids, 16, 295-301. [Google Scholar] [CrossRef] [PubMed]
[32] Mcclements, M.E. and Maclaren, R.E. (2017) Adeno-Associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes. The Yale Journal of Biology and Medicine, 90, 611-23.
[33] Costa Verdera, H., Kuranda, K. and Mingozzi, F. (2020) AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer. Molecular Therapy: The Journal of the American Society of Gene Therapy, 28, 723-746. [Google Scholar] [CrossRef] [PubMed]
[34] Fu, Q., Polanco, A., Lee, Y.S. and Yoon, S. (2023) Critical Challenges and Advances in Recombinant Adeno-Associated Virus (rAAV) Biomanufacturing. Biotechnology and Bioengineering, 120, 2601-2621. [Google Scholar] [CrossRef] [PubMed]
[35] Pfeiffer, F., Gröber, C., Blank, M., Händler, K., Beyer, M., Schultze, J.L., et al. (2018) Systematic Evaluation of Error Rates and Causes in Short Samples in Next-Generation Sequencing. Scientific Reports, 8, Article No. 10950. [Google Scholar] [CrossRef] [PubMed]
[36] 王国华, 吕军鸿, 雷晓玲, 等. 单分子PCR产物错误率分析[J]. 生物化学与生物物理进展, 2004, 31(2): 159-162.
[37] 刘姗姗, 岳素文, 江洪, 等. 一种新的引物二聚体形成机制[J]. 华中科技大学学报(医学版), 2014, 43(1): 53-58.
[38] Nikpay, M., Goel, A., Won, H.H., et al. (2015) A Comprehensive 1000 Genomes-Based Genome-Wide Association Meta-Analysis of Coronary Artery Disease. Nature Genetics, 47, 1121-1130. [Google Scholar] [CrossRef] [PubMed]
[39] The Coronary Artery Disease (C4D) Genetics Consortium (2011) A Genome-Wide Association Study in Europeans and South Asians Identifies Five New Loci for Coronary Artery Disease. Nature Genetics, 43, 339-344. [Google Scholar] [CrossRef] [PubMed]
[40] Huang, X. and Yang, Y. (2009) Innate Immune Recognition of Viruses and Viral Vectors. Human Gene Therapy, 20, 293-301. [Google Scholar] [CrossRef] [PubMed]
[41] Lek, A., Wong, B., Keeler, A., et al. (2023) Unexpected Death of a Duchenne Muscular Dystrophy Patient in an N-of-1 Trial of rAAV9-Delivered CRISPR-Transactivator. Preprint. [Google Scholar] [CrossRef] 
[42] Dhungel, B.P., Winburn, I., da Fonseca Pereira, C., Huang, K., Chhabra, A. and Rasko, J.E.J. (2024) Understanding AAV Vector Immunogenicity: From Particle to Patient. Theranostics, 14, 1260-1288. [Google Scholar] [CrossRef] [PubMed]
[43] Fan, H. and Johnson, C. (2011) Insertional Oncogenesis by Non-Acute Retroviruses: Implications for Gene Therapy. Viruses, 3, 398-422. [Google Scholar] [CrossRef] [PubMed]
[44] van der Loo, J.C.M., Swaney, W.P., Grassman, E., Terwilliger, A., Higashimoto, T., Schambach, A., et al. (2012) Critical Variables Affecting Clinical-Grade Production of the Self-Inactivating Gamma-Retroviral Vector for the Treatment of X-Linked Severe Combined Immunodeficiency. Gene Therapy, 19, 872-876. [Google Scholar] [CrossRef] [PubMed]
[45] Tenenbaum, L., Lehtonen, E. and Monahan, P. (2003) Evaluation of Risks Related to the Use of Adeno-Associated Virus-Based Vectors. Current Gene Therapy, 3, 545-565. [Google Scholar] [CrossRef] [PubMed]
[46] Guo, C., Ma, X., Gao, F. and Guo, Y. (2023) Off-Target Effects in CRISPR/Cas9 Gene Editing. Frontiers in Bioengineering and Biotechnology, 11, Article ID: 1143157. [Google Scholar] [CrossRef] [PubMed]
[47] Zuo, E., Sun, Y., Wei, W., Yuan, T., Ying, W., Sun, H., et al. (2019) Cytosine Base Editor Generates Substantial Off-Target Single-Nucleotide Variants in Mouse Embryos. Science, 364, 289-292. [Google Scholar] [CrossRef] [PubMed]
[48] Brokowski, C. and Adli, M. (2019) CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool. Journal of Molecular Biology, 431, 88-101. [Google Scholar] [CrossRef] [PubMed]
[49] Ran, F.A., Hsu, P.D., Lin, C., Gootenberg, J.S., Konermann, S., Trevino, A.E., et al. (2013) Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity. Cell, 154, 1380-1389. [Google Scholar] [CrossRef] [PubMed]
[50] Xiong, X., Liu, K., Li, Z., Xia, F., Ruan, X., He, X., et al. (2023) Split Complementation of Base Editors to Minimize Off-Target Edits. Nature Plants, 9, 1832-1847. [Google Scholar] [CrossRef] [PubMed]